Private equity investors are buying up U.S. health care at a remarkable pace. The impact on costs, quality and who gets care is not encouraging.
Private equity doesn’t usually make the news until something goes wrong. A nursing home closes. A hospital cuts staff. An ER gets too expensive to use. By then, the deal is years old, the returns are being counted and patients left behind have limited options.
This is the quiet story of how financial logic reshapes medical care and who ends up bearing the cost.
Private equity firms operate by acquiring businesses, restructuring them to increase profits, then selling them. This can extend to acquisition of health care locations like hospitals and private practices. Private equity ownership has expanded rapidly across nearly all health care settings, with roughly 11% of all nongovernmental hospital discharges in 2017 occurring at facilities with a history of private equity ownership. That number has only grown since. The core tension between the economics of return on investment and the ethics of health care access is becoming difficult to ignore.
The most immediate impact of private equity acquisition isn’t on quality or cost: It’s on who gets seen at all.
In urology practices, private equity affiliation was independently associated with lower Medicaid acceptance: Only 52% of private equity-affiliated practices accepted Medicaid, compared to 67% of independent practices. In otolaryngology (ENT), the gap was even starker, with 32% of non-private equity clinics offering telehealth options to new Medicaid patients, compared to 0% of private equity-owned clinics.
The economic logic isn’t hard to follow. Medicaid reimburses at lower rates than commercial insurance. Private equity firms, operating on return-focused timelines, have every incentive to tilt their patient mix toward higher-paying insurers. The Hospital Corporation of America, following a private equity acquisition, experienced roughly a 10% decline in traditional Medicare patients and a 30% decline in Medicaid outpatient procedures between 2003 and 2017. These aren’t accidents. They are strategies.
The cumulative effect of these access restrictions is the gradual construction of a two-tiered health care system, where one tier is for patients with commercial insurance, and the other increasingly threadbare tier is for everyone else.
Medicaid and Medicare aren’t fringe programs. They cover the elderly, the disabled, working adults who don’t have employer-sponsored insurance and children in lower-income households. Nearly 40% of Americans are on Medicare or Medicaid. When private equity-owned practices systematically deprioritize these patients, the burden doesn’t disappear, it shifts. It shifts to safety-net hospitals, community health centers and emergency departments, which are already strained and become the default option for anyone turned away elsewhere.
At the hospital level, private equity acquisition led to a 1% decrease in Medicare’s share of discharges between 2005 and 2017. That may sound small, but, scaled across hundreds of acquisitions and millions of patients, it represents a significant and deliberate reallocation of who gets access to well-resourced facilities. The patients being systemically excluded don’t stop needing care. They just receive it in worse conditions, later and with worse outcomes.
This dynamic compounds existing inequalities. Lower-income patients are more likely to be on Medicaid. Black and Hispanic Americans are disproportionately enrolled in Medicaid relative to their share of the population. When private equity firms optimize away from Medicaid patients, the resulting inequity is not race-neutral, as it maps onto existing disparities and deepens them.
For those who do get through the door, the bill is higher. Between 2005 and 2017, hospitals acquired by private equity charged $407 more per inpatient day, while physician practices increased charges by 20%, about $71 more per claim. Gastroenterology practices saw increases in colonoscopy prices, spending and utilization. At otolaryngology clinics, appointments at private equity-owned practices cost $291.18 on average, compared to $203.75 at independent practices, showing a near-$87 gap for the same appointment.
These increases hit people with high-deductible plans and those paying out of pocket the hardest. The populations least able to absorb price hikes are the ones most exposed to them.
What makes this dilemma more than an isolated pattern is how consistent the operational model is across settings — revenue optimization, staff reductions, selective patient intake. The Hospital Corporation of America lowered clinical thresholds for ED admissions to drive up volume while simultaneously cutting ED physician staffing by 25% in their second year of private equity ownership, demonstrating the paradoxical aim to acquire more patients but for less care per patient, all for better margins.
This is rational economic behavior. In a sector where the product is human health, this is also a serious public problem.
Health care and economics have always been at odds with one another. The market has genuine roles to play in driving efficiency, in allocating capital and in rewarding innovation. But health care is not a normal market. Patients are not typical consumers. Information is asymmetric, stakes are life and death and the most vulnerable patients, those who are elderly, disabled and lower-income, have the least power to push back.
As private equity continues expanding across health care, policymakers face a choice: treat these acquisitions as ordinary business transactions, or recognize them as decisions with direct consequences for health care equity.
The deal closes. The returns accumulate. And, somewhere down the line, a Medicaid patient calls a urology clinic and is told they are not accepted. That is not a market inefficiency. It is a policy failure.
